Non-myeloablative Autologous Haematopoietic Stem Cell Transplantation with Consolidation Therapy using Mitoxantrone as a Treatment Option in Multiple Sclerosis PatientsNovik AA1*, Kuznetsov AN2, Melnichenko VY3, Fedorenko DA4, Ionova TI5 and Gorodokin GV6
- *Corresponding Author:
- Andrei A. Novik
Department of Haematology and Cellular Therapy
Pirogov National Medical Surgical Center
70 Nizhnaya Pervomaiskaya str., 105 207 Moscow, Russia
Tel: +7 495 463 49 23
Fax: +7 495 463 49 23
E-mail: [email protected]
Received date: December 16, 2010; Accepted date: March 09, 2011; Published date: March 11, 2011
Citation: Novik AA, Kuznetsov AN, Melnichenko VY, Fedorenko DA, Ionova TI, et al. (2011) Non-myeloablative Autologous Haematopoietic Stem Cell Transplantation with Consolidation Therapy using Mitoxantrone as a Treatment Option in Multiple Sclerosis Patients. J Stem Cell Res Ther 1:102. doi:10.4172/2157-7633.1000102
Copyright: © 2011 Novik AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
High-dose immunosuppressive therapy with autologous haematopoietic stem cell transplantation (AHSCT) is a new and promising approach to multiple sclerosis (MS) treatment. Recently, the rationale of evolution from myeloablative to non-myeloablative (NM) transplant regimens has been discussed. We aimed to study clinical outcomes in MS patients after NM -AHSCT with consolidation therapy using Mitoxantrone. 55 MS patients were included in this study (mean age - 29.1; male/female - 23/32). Median EDSS at base-line - 4.0 (1.5-8.0), the mean follow-up duration - 26 months (range 9.0 - 50). No transplant related deaths were reported. There were no deaths in the study throughout the follow-up period. The mobilization and transplantation procedures were well tolerated. All the patients responded to the treatment. At long-term follow-up in the group with relapsingremitting MS improvement was demonstrated in 15 patients (58%) and stabilization in 11 (42%). No relapses throughout the whole follow-up period were found. In the group with progressive MS improvement was achieved in 15 patients (82%) and stabilization in 3 (18%). No active new or enlarging lesions were found according to MRI data. Thus, NM-AHSCT with consolidation therapy by Mitoxantrone appears to be a safe and effective treatment for MS. The results of our study support the feasibility of NM-AHSCT with consolidation therapy in this patient population.